Zurcher Kantonalbank (Zurich Cantonalbank) Alnylam Pharmaceuticals, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 54,570 shares of ALNY stock, worth $13.5 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

54,570

Previous 54,570 -0.0%

Holding current value

$13.5 Million

Previous $15 Million -0.0%

% of portfolio

0.05%

Previous 0.05%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$233.81 - $287.01 $2.55 Million - $3.13 Million	-10,915 Reduced 16.67%	54,570 $15 Million
Q2 2024 Jul 29, 2024	BUY	$143.31 - $247.0 $2.22 Million - $3.82 Million	15,471 Added 30.93%	65,485 $15.9 Million
Q1 2024 Apr 25, 2024	BUY	$146.51 - $198.2 $722,880 - $977,918	4,934 Added 10.94%	50,014 $7.47 Million
Q4 2023 Jan 30, 2024	BUY	$151.41 - $196.57 $3.4 Million - $4.42 Million	22,473 Added 99.41%	45,080 $8.63 Million
Q3 2023 Oct 25, 2023	BUY	$170.77 - $211.65 $375,864 - $465,841	2,201 Added 10.79%	22,607 $4 Million
Q2 2023 Aug 07, 2023	BUY	$185.01 - $212.05 $85,104 - $97,543	460 Added 2.31%	20,406 $3.88 Million
Q1 2023 May 08, 2023	BUY	$182.66 - $235.53 $188,505 - $243,066	1,032 Added 5.46%	19,946 $4 Million
Q4 2022 Feb 01, 2023	SELL	$185.53 - $241.31 $5.07 Million - $6.6 Million	-27,346 Reduced 59.11%	18,914 $4.49 Million
Q3 2022 Nov 09, 2022	BUY	$138.54 - $232.0 $28,539 - $47,792	206 Added 0.45%	46,260 $9.26 Million
Q2 2022 Aug 09, 2022	BUY	$120.42 - $169.29 $3.33 Million - $4.68 Million	27,645 Added 150.17%	46,054 $6.72 Million
Q1 2022 Apr 21, 2022	BUY	$127.18 - $173.91 $18,313 - $25,043	144 Added 0.79%	18,409 $3.01 Million
Q4 2021 Feb 01, 2022	SELL	$159.56 - $209.29 $1.41 Million - $1.85 Million	-8,836 Reduced 32.6%	18,265 $3.1 Million
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $131,386 - $160,783	774 Added 2.94%	27,101 $5.12 Million
Q2 2021 Jul 30, 2021	SELL	$128.63 - $176.89 $514 - $707	-4 Reduced 0.02%	26,327 $4.46 Million
Q1 2021 May 03, 2021	BUY	$126.83 - $175.69 $44,517 - $61,667	351 Added 1.35%	26,331 $3.72 Million
Q4 2020 Jan 28, 2021	BUY	$122.97 - $147.0 $12,542 - $14,994	102 Added 0.39%	25,980 $3.38 Million
Q3 2020 Nov 06, 2020	BUY	$121.19 - $165.49 $292,916 - $399,989	2,417 Added 10.3%	25,878 $3.77 Million
Q2 2020 Jul 28, 2020	SELL	$104.21 - $156.44 $108,378 - $162,697	-1,040 Reduced 4.24%	23,461 $3.48 Million
Q1 2020 May 06, 2020	BUY	$93.12 - $133.99 $97,124 - $139,751	1,043 Added 4.45%	24,501 $2.67 Million
Q4 2019 Jan 21, 2020	BUY	$74.51 - $124.23 $376,051 - $626,988	5,047 Added 27.41%	23,458 $2.7 Million
Q3 2019 Oct 18, 2019	BUY	$70.9 - $87.82 $70,758 - $87,644	998 Added 5.73%	18,411 $1.48 Million
Q2 2019 Jul 30, 2019	SELL	$65.86 - $92.79 $38,528 - $54,282	-585 Reduced 3.25%	17,413 $1.26 Million
Q1 2019 Apr 29, 2019	SELL	$72.76 - $93.45 $14,552 - $18,690	-200 Reduced 1.1%	17,998 $1.68 Million
Q4 2018 Jan 25, 2019	SELL	$62.67 - $88.33 $26,070 - $36,745	-416 Reduced 2.23%	18,198 $1.33 Million
Q3 2018 Nov 09, 2018	BUY	$87.52 - $122.67 $26,256 - $36,801	300 Added 1.64%	18,614 $1.63 Million
Q2 2018 Aug 06, 2018	SELL	$88.31 - $107.8 $151,981 - $185,523	-1,721 Reduced 8.59%	18,314 $1.8 Million
Q1 2018 May 03, 2018	BUY	$115.92 - $148.54 $41,847 - $53,622	361 Added 1.83%	20,035 $2.39 Million
Q4 2017 Jan 31, 2018	BUY	$114.49 - $139.98 $1.66 Million - $2.02 Million	14,462 Added 277.48%	19,674 $2.5 Million
Q3 2017 Nov 08, 2017	BUY	$72.53 - $118.27 $378,026 - $616,423	5,212	5,212 $612,000

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account

Zurcher Kantonalbank (Zurich Cantonalbank) Alnylam Pharmaceuticals, Inc. Transaction History